

JCWS/CS 08 OCT 2004



FENWICK & WEST LLP

SAN FRANCISCO OFFICE | EMBARCADERO CENTER WEST
 275 BATTERY ST., SUITE 1500 | SAN FRANCISCO, CA 94111
 TEL 415.875.2300 | FAX 415.281.1350 | WWW.FENWICK.COM

FACSIMILE TRANSMISSION

CONFIDENTIAL

DATE: October 7, 2004

CLIENT-MATTER No.: 23546-08072

Client ref. no. BIOL002US

TO:

NAME	FAX NO.	PHONE NO.
OFFICE OF INITIAL PATENT EXAMINATION CUSTOMER SERVICE CENTER USPTO	(503) 746-9195	

FROM: Susan T. Hubl
Reg. No. 47,668

PHONE: (415) 875-2316

SENT BY: Tracie Brooks

PHONE: (415) 875-2482

NUMBER OF PAGES WITH COVER PAGE: 9 ORIGINAL WILL NOT FOLLOW

MESSAGE:

Please See The Attached
REQUEST FOR CORRECTED FILING RECEIPT

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE OR THEIR DESIGNEE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPY OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, OR IF THEY ARE NOT CLEAR,
 PLEASE CALL Tracie Brooks AT (415) 875-2482 AS SOON AS POSSIBLE.

A1000/00103/SF/5121030.5

0001/PTO Rev. 10/95	U.S. Department of Commerce Patent and Trademark Office		
TRANSMITTAL FORM			
(to be used for all correspondence during pendency of filed application)			
Total Number of Pages in This Submission	8	Application Number	10/789,526
Filing Date	February 26, 2004		
First Named Inventor	George Tachas		
Group Art Unit Number	1651		
Examiner Name	Unassigned		
		Attorney Docket Number	23546-08072US (Client No: B1OL0002US)

ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Check Enclosed <input type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Response to Notice to File Missing Parts <input type="checkbox"/> Assignment & Recordation Cover Sheet <input type="checkbox"/> Declaration <input type="checkbox"/> Information Disclosure Statement & PTO/SB/08A <input type="checkbox"/> Copies of IDS Cited References <input checked="" type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Request for Correction of Recorded Assignment <input type="checkbox"/> Preliminary Amendment: [] Page(s) <input type="checkbox"/> After Final <input type="checkbox"/> Status Request <input type="checkbox"/> Revocation and Substitute Power of Attorney		<input type="checkbox"/> Issue Fee Transmittal <input type="checkbox"/> Letter to Chief Draftsperson <input type="checkbox"/> Formal Drawing(s): <input type="checkbox"/> [] Sheet(s) of Figure(s) [] <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> After Allowance Communication to Group <input checked="" type="checkbox"/> Fax cover sheet <input checked="" type="checkbox"/> Copies of Notices of Recordation (4 sheets total)	
REMARKS:			

SIGNATURE OF ATTORNEY OR AGENT			
Signature:	<i>Susan T. Hubl</i>		
Attorney/Reg. No.:	Susan T. Hubl, Reg. No. 47,868		Dated: October 7, 2004

CERTIFICATE OF FACSIMILE TRANSMISSION			
I hereby certify that this correspondence, including the enclosures identified above, is being transmitted on the date shown below via facsimile to: Commissioner for Patents at the facsimile number indicated below.			
Signature:	<i>Susan T. Hubl</i>		
Typed or Printed Name:	Susan T. Hubl		Dated: October 7, 2004
Facsimile Number:	1-703-746-9195		

23546-08072/SF/5122693.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	George Tachas, et al.
APPLICATION NO.:	10/789,526
FILING DATE:	February 26, 2004
TITLE:	MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION
EXAMINER:	Unassigned
GROUP ART UNIT:	1651
ATTY. DKT. NO.:	23546-08072/US (BIOL0002US)
CERTIFICATE OF MAILING/TRANSMISSION	
I hereby certify that this correspondence is being transmitted on the date shown below to the US Commissioner for Patents, via facsimile number 703-746-9195	
Dated:	10/7/04
By:	Susan T. Hubl
Susan T. Hubl, Ph.D., Reg. No.: 47,668	

COMMISSIONER FOR PATENTS
 OFFICE OF INITIAL PATENT EXAMINATION
 CUSTOMER SERVICE CENTER
 P.O. BOX 1450
 ALEXANDRIA, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Enclosed is a copy of the Official Filing Receipt. It contains the following error:

The "Assignment For Published Patent Application" section is missing the name of the second Assignee. The Filing Receipt should be corrected to list "Antisense Therapeutics, Inc." along with "Isis Pharmaceuticals, Inc.". Please see the marked up copy of the official filing receipt attached. The correct "Assignment For Published Patent Application" information is evidenced by the Notices of Recordation on file for this matter, copies of which are enclosed.

Please issue a corrected Filing Receipt rectifying this error.

Respectfully submitted,
 GEORGE TACHAS, ET AL.

Dated: 10/7/04

By: Susan T. Hubl

Susan T. Hubl, Ph.D. Patent Agent
 Reg. No.: 47,668
 Fenwick & West LLP
 Silicon Valley Center
 801 California Street
 Mountain View, CA 94041
 Tel.: (415) 875-2316
 Fax.: (650) 938-5200

23546-08072/SF/5129781.1

UNITED STATES PATENT AND TRADEMARK OFFICE

Isis Ref B10L0002 US

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/789,526	02/26/2004	1651	1608	23546-08072		45	6

35807
FENWICK & WEST LLP
 801 CALIFORNIA STREET
 MOUNTAIN VIEW, CA 94014

Fenwick & West

AUG 30 2004

Received

CONFIRMATION NO. 9932

UPDATED FILING RECEIPT



OC000000013661115

Date Mailed: 08/27/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

George Tachas, Melbourne, AUSTRALIA;
 Kenneth W. Dobie, Del Mar, CA;
 Ravi Jain, Carlsbad, CA;
 Christopher Belyea, Melbourne, AUSTRALIA;
 Mark A. Heffeman, Melbourne, AUSTRALIA;

Assignment For Published Patent Application

Isis Pharmaceuticals, Inc., Carlsbad, CA;
ANTI SENSE THERAPEUTICS, INC.

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/451,456 02/28/2003
 and claims benefit of 60/490,230 07/25/2003 *
 (*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

If Required, Foreign Filing License Granted: 04/13/2004

Projected Publication Date: 12/09/2004

Non-Publication Request: No

Early Publication Request: No

Title

Modulation of growth hormone receptor expression and insulin-like growth factor expression

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).